News
June 11, 2021•News, Past Events
Facebook Live: What Does Aducanumab Mean for Alzheimer’s?
Dr. Dale Bredesen and Julie Gregory discussed the FDA’s approval Biogen’s drug Aduhelm and the ramifications for those seeking treatment for Alzheimer’s. Read More »
June 9, 2021•News
Aducanumab vs. the ReCODE Protocol
The recently FDA approved Aduhelm did not improve cognition but mildly slowed down disease progression with dangerous side effects compared to the ReCODE Protocol, which in a recent trial demonstrated that 84% of the participants improved cognition with health optimization as the only side effect. Read More »
June 9, 2021•Interviews, News
FDA Approves New Alzheimer’s Drug Despite Little Evidence it Works
Dr. Bredesen speaks with CBN News’ reporter, Lorie Johnson, about the recent FDA approval of the Alzheimer’s drug Aduhelm. Read More »
June 7, 2021•From Ram Rao, News
The Ill Effects of Prolonged Sitting
Dr. Ram Rao discusses how prolonged sitting has serious detrimental effects on our bodies and health. Read More »
June 7, 2021•From Julie Gregory, Insider Strategies, News
Julie Gregory discusses the importance of stimulating the lymphatic system to upregulate our body’s ability to detoxify. Read More »
June 7, 2021•From Dr. Bredesen, News
Finally — Clinical Trial Demonstrates Reversal of Cognitive Decline
Dr. Bredesen writes about his successful clinical trial using precision medicine that addresses the multiple causes of Alzheimer’s. Read More »
May 29, 2021•News
Facebook Live: Clinical Trial Discussion
Dr. Dale Bredesen and Julie Gregory, were joined by Dr. Kat Toups to discuss their recently published Alzheimer’s clinical trial. Read More »
May 26, 2021•Interviews, News
Precision Medicine Study Points to Promising New Approach in Alzheimer’s
BioSpace’s Heather McKenzie spoke with Dr. Bredesen about the recently published results from the study “Precision Medicine Approach to Alzheimer’s Disease: Successful Proof-of-Concept Trial.” Read More »